CagriSema
Also known as: Cagrilintide + Semaglutide, Dual GLP-1/Amylin Agonist
CagriSema combines cagrilintide (an amylin analog) with semaglutide (a GLP-1 receptor agonist) to create a dual-action weight loss compound that targets multiple metabolic pathways.
CagriSema is a Approximately 8,500 Da (combined) research peptide. CagriSema combines cagrilintide (an amylin analog) with semaglutide (a GLP-1 receptor agonist) to create a dual-action weight loss compound that targets multiple metabolic pathways.
Also called: Cagrilintide + Semaglutide, Dual GLP-1/Amylin Agonist
Approximately 8,500 (combined)
Molecular Weight
Daltons
3
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
0.5-2.4
Typical Dose
mg
Overview
CagriSema represents a novel approach to weight management by combining two distinct mechanisms of action in a single compound. The cagrilintide component activates amylin receptors in the brain, promoting satiety and slowing gastric emptying, while semaglutide activates GLP-1 receptors to enhance insulin sensitivity and suppress appetite. This dual-receptor targeting approach has shown superior weight loss results compared to either compound alone. The combination works synergistically by addressing multiple aspects of metabolic dysfunction, including appetite regulation, glucose homeostasis, and energy expenditure. Research indicates that CagriSema can produce significant weight reduction while improving metabolic markers associated with type 2 diabetes and metabolic syndrome.
Key Takeaways: CagriSema
- Strongest evidence supports CagriSema for superior weight loss and enhanced appetite control
- Research doses typically range from 0.5 to 2.4 mg via subcutaneous
- 3 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 4-7 days
- 3 cited research studies in this guide
Mechanism of Action
CagriSema operates through dual receptor activation. Cagrilintide binds to amylin receptors (AMY1, AMY2, AMY3) primarily located in the area postrema and nucleus tractus solitarius of the brainstem, triggering satiety signals and reducing food intake. Simultaneously, semaglutide activates GLP-1 receptors throughout the body, stimulating insulin secretion in a glucose-dependent manner, inhibiting glucagon release, and slowing gastric emptying. This combination creates complementary effects on appetite suppression, glucose regulation, and weight management that exceed the sum of their individual actions.
Research Benefits
CagriSema at a Glance
CagriSema operates through dual receptor activation.
Superior Weight Loss
Strong EvidenceClinical trials demonstrate weight reductions of 15-25% from baseline when combined with lifestyle modifications, significantly exceeding results from either component alone
Enhanced Appetite Control
Strong EvidenceDual pathway activation creates more robust and sustained appetite suppression through complementary amylin and GLP-1 receptor signaling
Improved Glycemic Control
Strong EvidenceReduces HbA1c levels by 1.5-2.3% while maintaining glucose-dependent insulin action, minimizing hypoglycemia risk
Cardiovascular Risk Reduction
Moderate EvidencePreliminary data suggests improvements in blood pressure, lipid profiles, and inflammatory markers associated with cardiovascular disease
Body Composition Improvements
Moderate EvidencePreferentially reduces visceral fat mass while preserving lean muscle tissue when combined with resistance training
Metabolic Flexibility Enhancement
PreliminaryImproves substrate utilization and metabolic rate through combined effects on glucose and lipid metabolism
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Weight loss research | 0.5–2.4 mg | subcutaneous |
| Metabolic research | 0.25–1 mg | subcutaneous |
Frequency
Once weekly
Timing
Same day each week, with or without food
Cycle Length
12-24 weeks minimum for research protocols
Research Notes
- 1Start with lowest effective dose and titrate based on tolerance
- 2Dose escalation typically occurs every 4 weeks
- 3Rotate injection sites to prevent lipodystrophy
- 4Research protocols often include 4-week washout periods
- 5Co-administration with other GLP-1 agonists is contraindicated
Reconstitution Guide
Standard Reconstitution
Vial Size
3 mg
Bacteriostatic Water
0.6 mL
Concentration
50 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
CagriSema vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0.6 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 28 days after reconstitution when refrigerated.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
28 days after reconstitution when refrigerated
Important Notes
- •Use bacteriostatic water for injection
- •Gently swirl to dissolve, do not shake vigorously
- •Solution should be clear and colorless after reconstitution
- •Store in original vial with rubber stopper
- •Protect from light and freezing temperatures
CagriSema Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
CagriSema Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (70-85% of users initially)
- !Vomiting and gastric upset
- !Diarrhea or constipation
- !Injection site reactions (redness, swelling)
- !Fatigue and weakness
- !Headaches
- !Dizziness
- !Decreased appetite (therapeutic effect)
- !Potential pancreatitis (rare but serious)
- !Hypoglycemia when combined with insulin or sulfonylureas
Potential Interactions
- ⚡Insulin and other diabetes medications may require dose adjustments
- ⚡Oral medications may have altered absorption due to delayed gastric emptying
- ⚡Warfarin and other anticoagulants may require monitoring adjustments
- ⚡Digoxin levels may be affected by changes in gastric motility
- ⚡Acetaminophen absorption may be delayed but not reduced
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and safety of cagrilintide for weight management in adults with overweight or obesity
Phase 2 trial demonstrating dose-dependent weight loss with cagrilintide, establishing foundation for combination development
Dual amylin and GLP-1 receptor agonism for enhanced metabolic benefits
Mechanistic study showing synergistic effects of combined amylin and GLP-1 receptor activation on weight loss and glycemic control
Safety and tolerability profile of combination peptide therapy in obesity
Comprehensive safety analysis of dual-mechanism peptide combinations, informing optimal dosing strategies
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
CagriSema combines semaglutide (the active ingredient in Ozempic) with cagrilintide for enhanced weight loss. Clinical data suggests 20-40% greater weight reduction compared to semaglutide alone through dual receptor activation targeting both GLP-1 and amylin pathways.
Research protocols typically start at 0.25-0.5mg weekly, escalating every 4 weeks up to 2.4mg maximum. The once-weekly injection schedule matches other GLP-1 medications, with dose titration based on tolerance and efficacy.
Initial appetite suppression occurs within 1-2 weeks, with noticeable weight loss typically beginning by week 4-6. Maximum benefits are usually achieved after 12-16 weeks of consistent use in research settings.
Like other GLP-1 receptor agonists, CagriSema carries a potential risk of pancreatitis. Research participants with history of pancreatitis or severe gastrointestinal disease are typically excluded from studies. Symptoms include severe abdominal pain radiating to the back.
Gastrointestinal effects dominate the side effect profile, with nausea affecting 70-85% of users initially, followed by vomiting, diarrhea, and injection site reactions. Most GI symptoms improve significantly after 4-8 weeks of consistent dosing.
Research indicates CagriSema improves glycemic control in type 2 diabetes while promoting weight loss. However, insulin and other diabetes medications typically require dose reductions to prevent hypoglycemia. Continuous glucose monitoring is recommended during research protocols.
Reconstituted CagriSema must be refrigerated at 2-8°C and used within 28 days. Store in the original vial, protect from light and freezing, and inspect for clarity before each injection. Cloudy or discolored solutions should be discarded.
CagriSema should not be combined with other GLP-1 receptor agonists due to overlapping mechanisms. Research protocols typically exclude participants using other incretin-based therapies. Combination with traditional appetite suppressants requires careful monitoring.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.